Mast Therapeutics (SVRA) Receiving Somewhat Positive Media Coverage, Study Finds

Headlines about Mast Therapeutics (NASDAQ:SVRA) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mast Therapeutics earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.0573234229248 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Mast Therapeutics (NASDAQ SVRA) opened at $13.00 on Friday. The company has a market cap of $386.75, a PE ratio of -3.10 and a beta of 0.18. Mast Therapeutics has a fifty-two week low of $4.60 and a fifty-two week high of $17.19. The company has a current ratio of 9.15, a quick ratio of 9.15 and a debt-to-equity ratio of 0.20.

Mast Therapeutics (NASDAQ:SVRA) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.12. analysts forecast that Mast Therapeutics will post -1.64 EPS for the current year.

Several analysts have recently weighed in on the stock. BidaskClub downgraded shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Roth Capital reaffirmed a “buy” rating and issued a $40.00 target price on shares of Mast Therapeutics in a report on Wednesday, September 27th. Zacks Investment Research downgraded shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 23rd. Ladenburg Thalmann Financial Services initiated coverage on shares of Mast Therapeutics in a report on Wednesday, January 3rd. They set a “buy” rating and a $35.00 price objective on the stock. Finally, ValuEngine downgraded shares of Mast Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $23.58.

In other Mast Therapeutics news, Director Yuri Pikover bought 50,000 shares of the business’s stock in a transaction on Friday, October 27th. The stock was bought at an average price of $7.85 per share, for a total transaction of $392,500.00. Following the completion of the transaction, the director now owns 150,000 shares in the company, valued at approximately $1,177,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Mast Therapeutics (SVRA) Receiving Somewhat Positive Media Coverage, Study Finds” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at

Mast Therapeutics Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Insider Buying and Selling by Quarter for Mast Therapeutics (NASDAQ:SVRA)

Receive News & Ratings for Mast Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply